Spontaneous Irs1 passenger mutation linked to a gene-targeted SerpinB2 allele by Westrick, R. J. et al.
Spontaneous Irs1 passenger mutation linked to
a gene-targeted SerpinB2 allele
Randal J. Westricka,b, Karen L. Mohlkec, Lindsey M. Koreptad, Angela Y. Yangb, Goujing Zhud, Sara L. Manningb,
Mary E. Winnd, Kristiann M. Doughertyd, and David Ginsburga,b,d,1
aLife Sciences Institute and bHoward Hughes Medical Institute, University of Michigan, Ann Arbor, MI 48109; cDepartment of Genetics, University of North
Carolina, Chapel Hill, NC 27599; and dDepartments of Internal Medicine, Human Genetics, and Pediatrics, University of Michigan, Ann Arbor, MI 48109
Contributed by David Ginsburg, August 16, 2010 (sent for review May 6, 2010)
In characterizing mice with targeted disruption of the SerpinB2
gene, we observed animals that were small at birth with delayed
growth and decreased life expectancy. Although this phenotype
cosegregated with homozygosity for the inactive SerpinB2 allele,
analysis of homozygous SerpinB2-deficient mice derived from two
additional independent embryonic stem (ES) cell clones exhibited
no growth abnormalities. Examination of additional progeny from
the original SerpinB2-deficient line revealed recombination be-
tween the small phenotype (smla) and the SerpinB2 locus. The
locus responsible for smla was mapped to a 2.78-Mb interval ap-
proximately 30 Mb proximal to SerpinB2, bounded by markers
D1Mit382 and D1Mit216. Sequencing of Irs1 identified a nonsense
mutation at serine 57 (S57X), resulting in complete loss of IRS1
protein expression. Analysis of ES cell DNA suggests that the
S57X Irs1 mutation arose spontaneously in an ES cell subclone
during cell culture. Although the smla phenotype is similar to pre-
viously reported Irs1 alleles, mice exhibited decreased survival, in
contrast to the enhanced longevity reported for IRS1 deficiency
generated by gene targeting. This discrepancy could result from
differences in strain background, unintended indirect effects of
the gene targeting, or the minimal genetic interference of the
S57X mutation compared with the conventionally targeted Irs1-
KO allele. Spontaneous mutations arising during ES cell culture
may be a frequent but underappreciated occurrence. When linked
to a targeted allele, such mutations could lead to incorrect assign-
ment of phenotype and may account for a subset of markedly
discordant results from experiments independently targeting the
same gene.
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Gene targeting in embryonic stem (ES) cells has revolution-ized the use of the mouse as a model organism for studying
gene function in vivo, providing powerful insights into the
functions of individual genes and their relationships to complex
phenotypes (1). However, this methodology is technically de-
manding, expensive, and time-consuming, discouraging the pro-
duction of multiple engineered mouse lines from independently
targeted ES cell clones for confirmation of observed phenotypes.
As a result, many “knockout” mouse reports are based on the
analysis of animals derived from a single targeted ES cell clone.
In some cases, a functional KO is obtained, despite an aberrant
gene targeting event with only partial deletion or rearrangement
at the targeted locus (2).
In cases in which the same locus has been independently tar-
geted by more than one strategy, important and surprising dif-
ferences have occasionally been observed. The explanations for
such discrepancies include variation in genetic strain background
of the gene targeted mice and structural differences in the tar-
geted alleles (3–5). Polymorphisms in the genomic region sur-
rounding the targeted locus between the ES cell line used for
targeting and the strains used for mating, called “passenger
genes,” can be particularly confounding (6). Gene targeting may
also unexpectedly interfere with the expression of a nearby gene,
as has been observed for retained selectable marker cassettes (7–
9) and probably contributes to the disparate phenotypes repor-
ted for five independent Myf-5/Mrf4 targeted alleles (5, 10). It is
likely that other artifacts resulting from the process of gene
targeting remain to be discovered (8).
The protein product of the SerpinB2 gene, plasminogen acti-
vator inhibitor-2 (PAI-2), is a member of the serine protease
inhibitor family. Similar to PAI-1, the primary physiological
function of PAI-2 is thought to be regulation of the plasminogen
activators urokinase and tissue plasminogen activator in the ex-
travascular compartment (11–13). Although PAI-2 deficiency has
not yet been identified in humans, it has been proposed to play
a role in additional processes including apoptosis, tumor metas-
tasis, embryo implantation, macrophage survival, and fibrinolysis
(14, 15). The high plasma levels observed during pregnancy also
suggest that PAI-2 could be important for placental maintenance
or during embryonic development (16). To investigate the in vivo
function of PAI-2, we previously generated three SerpinB2-KO
mouse lines derived from three independent ES cell clones
identified as 15B11, 10G3, and 13B5 (17). SerpinB2-deficient
mice derived from the 10G3 and 13B5 clones exhibited no overt
phenotype, even in the context of concomitant PAI-1 deficiency
(17). However, a distinct phenotype, termed smla because of the
runted and scruffy appearance of the animals, was noted in the
majority of homozygous SerpinB2-deficient mice obtained from
the 15B11 line.
We now report the identification of the specific molecular
defect responsible for the smla phenotype as a nonsense muta-
tion (S57X) in a nearby gene, insulin receptor substrate 1 (Irs1),
that appears to have originated in the ES cells used for the
gene targeting.
Results
smla Phenotype Associated with SerpinB2 Deficiency. To generate
SerpinB2-deficient mice, three targeted ES cell clones (15B11,
10G3, and 13B5) were injected into C57BL/6J blastocysts (17).
Six chimeric males obtained from clone 15B11 were used to
generate mice heterozygous for SerpinB2, and 13 F1 heterozy-
gous matings were initiated. Analysis of F2 progeny alive at
weaning (3 wk of age) revealed a divergence from the expected
Mendelian ratios, with a trend toward decreased numbers of
SerpinB215B11−/− pups (P ≈ 0.051) that reached significance when
analyzing only female offspring (P < 0.01; Table 1). As evident
in Fig. 1A, SerpinB215B11−/− mice also exhibited significantly
decreased lifespan (P < 0.05), with loss of SerpinB215B11−/− be-
ginning shortly after weaning. As seen in Fig. 1B, adult Ser-
pinB215B11−/− mice are noticeably smaller than their WT and
heterozygous littermates. Normalized weights of F2 progeny
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stratified by SerpinB2 genotype are shown in Fig. 2. Consistent
with their visual appearance, the normalized weight ratios of
SerpinB215B11−/− mice are significantly lower (0.62 ± 0.22)
compared with WT littermate controls (1.0 ± 0.09), whereas no
significant difference was observed in the weight ratios of Ser-
pinB2 (15B11) heterozygotes (0.94 ± 0.18) compared with WT.
Weight data obtained from birth to 6 wk for progeny from two
F1 heterozygous matings demonstrated decreased size of the
SerpinB2−/− detectable at birth and more obvious at 2 wk of age.
Despite their small stature, healthy adult male and female Ser-
pinB215B11−/− mice were fertile. Null females were able to carry
null pups to term. Postmortem examination of smla mice iden-
tified no significant gross or microscopic abnormalities aside
from the proportionally decreased stature and muscle wasting in
a subset of mice. As previously reported, the smla phenotype was
not observed in null mice from the SerpinB2 (10G3) and Ser-
pinB2 (13B5) lines (17).
smla Is Not a Result of Maternal Effect or Known Infectious Path-
ogens. Cross-fostering experiments excluded a maternal effect as
the cause of the smla phenotype. Sera collected from smla mice
were found to be negative for a panel of common infectious agents
(Materials and Methods). Complementation testing between the
SerpinB2 (15B11) and SerpinB210G3/SerpinB2 (13B5) alleles failed
to generate any progeny with the smla phenotype, excluding
a vertically transmitted infection or other maternally transmitted
factor(s) that depend on the SerpinB2-deficient genotype.
Analysis of Targeting at the SerpinB2 Locus. SerpinB2 (15B11) was
identified as a homologous recombinant by Southern blot anal-
ysis, as previously described (17). Probes were derived from 5′
sequence located outside the targeting vector and a 3′ fragment
from within the targeting vector. No second site of integration
was detected (17). A neo probe detected a fragment of the
expected size from all three targeted clones, without additional
fragments that would indicate another insertion site. In addition,
a cDNA probe demonstrated complete deletion of all SerpinB2
coding sequences.
Segregation of smla Phenotype from SerpinB2 Locus. With the
continued generation of progeny from F1 intercrosses of the smla
line, normal-sized SerpinB215B11−/− (red bars within black circle,
Fig. 2) and small-sized SerpinB215B11+/− (yellow bars within red
circle, Fig. 2) were occasionally detected. Genotypes in animals
with discordant phenotypes were confirmed by Southern blot
analysis. The number of discordant animals was consistent with
a second locus for smla located approximately 11 cM from the
SerpinB2 gene (Table 2).
smla Gene Located 26–28 Mb Centromeric to SerpinB2. Analysis of
mapping crosses using the CASA/RK strain revealed smla mice
among the F2 progeny in this mixed genetic background at the
expected Mendelian frequency. Eighteen smla mice were chosen
for genetic analysis proximal and distal to SerpinB2 on chromo-
some 1. Based on the recombinant mice identified in the genetic
region proximal to SerpinB2, smla was localized between markers
D1Mit216 and D1Mit8, approximately 27 Mb proximal to the
SerpinB2 locus on chromosome 1 (Fig. 3). The genotyping of 265
additional small and normally sized F2 progeny at D1Mit216 and
D1Mit8 and three additional markers located between D1Mit216
and D1Mit8 identified an additional recombinant, 8F4 (Fig. 3,
bounded by the gold box), that, along with mice 8C5 and 2A8,
localized smla to a 2.78-Mb interval between D1Mit216 (79.8
Mb) and D1Mit382 (82.7 Mb).
An S57X (C170A) Mutation in Irs1 Is Responsible for smla. There are
eight RefSeq genes within the 2.78-Mb candidate interval, in-
cluding Cul-3 (cullin-3), Serpine2 (protease nexin 1), Dock10, Irs1
(insulin receptor substrate 1), Rhbdd1 (rhomboid domain con-
taining protein 1), Col4a4 (procollagen, type IV, alpha 4),
Fam124D, and 943001J16Rik (Fig. 3, Bottom). Sequence analysis
of the single Irs1 coding exon PCR-amplified from genomic
DNA obtained from a smla mouse identified a single C-to-A
transversion at nucleotide 170, resulting in a serine-to-nonsense
mutation (S57X) at codon 57 (Fig. 4A). Genotyping of a subset
of the mice with the smla phenotype for the C170A point mu-
tation demonstrated complete concordance between the smla
phenotype and homozygosity for the S57X mutation (n = 23).
Table 1. Genotypic analysis of weaning age F2 progeny (15B11
cell line)
Sex SerpinB2 +/+ SerpinB2 +/− SerpinB2 −/− Total P value
Male 53 (27.6%) 87 (45.3%) 52 (27.1%) 192 ≈0.5
Female 56 (30.1%) 106 (57.0%) 24 (12.9%) 186 <0.001






Fig. 1. Gross appearance and reduced survival of homozygous SerpinB2-
deficient mice. (A) Kaplan–Meier survival analysis of WT SerpinB2 homozy-
gous null (−/−) mice (n = 24) and heterozygous (+/−; n = 51) and WT (+/+; n = 25)
littermates. A significant loss of homozygotes is seen, beginning at postnatal
day 21, compared with WT and heterozygous animals (P < 0.05 and P < 0.01,
respectively). (B) Five littermates from an F1 intercross. The smla phenotype,
indicated by the white arrows, is characterized by a grossly smaller ap-
pearance compared with WT and heterozygous littermates.
Fig. 2. Histogram of normalized weights of F2 mice from an F1 intercross
of SerpinB2+/− mice. Only mice from litters containing at least one SerpinB2
WT mouse were included (n = 228). With the continued generation of
progeny from F1 intercrosses of the smla line, occasional normally sized
SerpinB215B11−/− (red bars within the black circle) and small-sized Ser-
pinB215B11+/− mice (yellow bars within the red circle) were observed. These
data suggest the presence of recombinants between SerpinB2 and the locus
responsible for the smla phenotype.






The S57X mutation was absent from the two other SerpinB2
targeted null lines, as well as from WT C57BL/6J and 129S1/
SvIMJ mice.
S57X smla Mutation Results in Loss of Irs1 Protein Expression. The
truncating S57X mutation is predicted to lead to the complete
absence of IRS1 protein (Fig. 4B). Western blot analysis of
quadriceps muscle tissue total cell extract demonstrated the
expected approximate 145-kDa protein in tissue from WT and
heterozygous S57X mice, with no detectable protein in tissue
from mice homozygous for the S57X mutation (Fig. 4C).
smla Phenotype Is Independent of SerpinB2 Genotype. To exclude
a contribution of SerpinB2 deficiency to the smla phenotype,
mice recombinant between SerpinB2 and the S57X mutation
were crossed to generate mice homozygous for Irs1 S57X and
WT at SerpinB2. No obvious difference in phenotype was ob-
served among Irs1 S57X homozygous littermates with respect to
SerpinB2 genotype.
Increased Lethality of Irs1 Deficiency on C57BL/6J Strain Background.
As detailed earlier, the Irs1 S57X homozygous mice on a mixed
129/C57BL/6J genetic background demonstrate decreased long-
term survival and runting. With further backcrossing (N3–N4
generation) into the C57BL/6J background, a marked increase in
lethality was observed, with less than 2% of Irs1 S57X homo-
zygotes surviving to 2 wk of age (Table 3, line 1). An outcross of
Irs1 S57X heterozygotes to the 129S1/SvIMJ strain followed by
F1 intercross resulted in improved survival at 2 wk, with ap-
proximately 25% of the F2 weanlings observed to be S57X
homozygotes (Table 3, line 2).
Discussion
We previously reported the analysis of SerpinB2-deficient mice
generated by gene targeting (17). Two independently targeted
ES lines revealed no discernable abnormalities in growth, sur-
vival, development, wound healing, or macrophage recruitment
(17). However, a third independent SerpinB2-deficient line
exhibited a distinct runted phenotype, which we designated smla.
Recombination between the SerpinB2-null allele and the smla
phenotype was observed and exploited to map smla to a 2.78-Mb
nonrecombinant interval on chromosome 1, 27 Mb proximal to
Table 2. Genetically informative F2 progeny with phenotype/genotype mismatches scored as recombinants in
(smla/CASA/Rk) F1 intercross progeny





Male 39 Normal 28 smla — —
7 smla 4 Normal 11/110 0.1
Female 55 Normal 17 Normal — —
1 smla 12 smla 13/114 0.11
Total 102 61 24/224 0.11
Progeny were categorized as “normal” or “smla” for SerpinB2 +/− and −/− genotypes (mice with normalized weight ratios lower than
0.7 were considered smla, as described in Materials and Methods). SerpinB2+/− smla animals are presumably homozygous for smla,
suggesting that a recombination has occurred on one allele between SerpinB2 and the smla locus. Similarly, normal-sized SerpinB2−/−
mice have presumably recombined on at least one allele between SerpinB2 and the smla locus. Two recombinant meioses are possible
























Fig. 3. Genetic map of the smla region on distal mouse chromosome 1. Blue
boxes indicate the inheritance of two M. musculus alleles. Yellow boxes
correspond to inheritance of one Mus castaneus and one M. musculus allele.
The initial phase of mapping localized the candidate interval between
markers D1Mit216 and D1Mit8, shown in light gray. Recombinant 8F4,
highlighted by the gold box, narrowed the right side of the interval to
D1Mit382. Shown at the bottom is a schematic of the eight RefSeq genes












Fig. 4. Sequencing and Western blotting of Irs1 from smla mice. (A) Irs1
sequence tracings in the vicinity of nucleotide 170. Light blue shading
highlights the presence of a “C” in the WT (Irs1+/+) and an “A” in the ho-
mozygous deficient (Irs1−/−) DNA sequence. This mutation results in Ser57X
of IRS1. (B) Schematic of IRS1 protein showing that the S57X mutation dis-
rupts all functional domains. Domains: PH, pleckstrin homology; PTB, phos-
photyrosine binding, SAIN, Shc and IRS1 NPXY binding. (C) IRS1 Western blot
of muscle tissue. There is complete absence in IRS1−/− and a strong signal
corresponding to IRS1 protein in the IRS1+/+ at 145 KDa. IRS1+/− displays an
intermediate signal, consistent with one functional allele.
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SerpinB2. DNA sequence analysis of Irs1, a candidate gene
within this nonrecombinant interval, identified a S57X nonsense
mutation that truncates the protein at amino acid 57, disrupting
all identified functional domains of Irs1. Western blot analysis of
muscle tissue from S57X homozygotes revealed no reactivity
compared with tissue from heterozygous and WT mice. IRS1 is
a 1,231-amino acid intracellular adaptor molecule first identified
as a downstream mediator of insulin receptor signaling, but also
linked to several other signal transduction pathways essential for
cell growth and proliferation (18, 19). Previously reported gene
targeted Irs1-deficient mice (20–22) share a postnatal growth
defect, with birth weights at 40% to 60% compared with het-
erozygous or WT littermates. However, in contrast to our data,
no significant embryonic or postnatal lethality was observed.
In addition, Selman et al. recently reported that C57BL/6 con-
genic Irs1-deficient female mice display increased longevity
compared with heterozygote and WT controls (23). These results
contrast with our observation of early lethality of homozygous
Irs1 S57X mice N3/N4 on the C57BL/6J background (compared
with normal survival at 2 wk on a mixed C57BL/6J-129S1Sv/IMJ
background).
There are several possible explanations for this discrepancy in
phenotype. The Irs1-null allele reported here results from a sin-
gle point mutation, with no other associated genomic alterations.
In contrast, the previously reported null alleles contain an in-
sertion 2.6 kb 3′ to the translation initiation start site or a de-
letion of −77 to +179 (21, 22). These changes in genomic
structure could conceivably interfere with the expression of
a nearby gene, as has been previously reported for gene targeted
alleles at the granzyme B and β globin loci (7, 9), and the Myf-5/
Mrf4 genes (5, 10).
Mouse genetic background has a critical effect on many phe-
notypes (24), with strain-specific modifiers and genetic inter-
actions previously reported in the insulin receptor pathway (20,
25, 26). Mice heterozygous for both insulin receptor (Insr) and
Irs1 mutations exhibit dramatically different phenotypes on the
129Sv, C57BL/6, and DBA/2 genetic backgrounds, with C57BL/6
mice displaying marked hyperglycemia and hyperinsulinemia
(27). These or similar strain modifiers could contribute to the
differences in survival observed for the Irs1 S57X congenic mice
on different backgrounds (Table 3), as well as with previously
reported gene targeted Irs1 mutants.
Even established inbred mouse strains maintained in isolation
from one another may effectively become substrains separated
from each other by hundreds of generations (28). In addition,
Watkins-Chow et al. recently discovered an intrastrain copy
number variant of the insulin degrading enzyme (Ide) present in
Hardy-Weinberg equilibrium in the inbred C57BL/6J mouse
population at Jackson Laboratories (29). It is possible that this or
other subtle variations within C57BL/6J could contribute to
discordant survival observed in the current and previous reports.
Finally, differential contributions from retained 129Sv sequences
within the KO congenic intervals also cannot be excluded.
A spontaneous Irs1 mutation in an inbred C3.SW-H2b/SnJ
mouse strain was also recently reported (30). Mice homozygous
deficient for this mutation exhibit hyperinsulinemia, are small in
stature, and exhibit bone abnormalities, with no reported effect
on longevity (30). The normal lifespan observed in these mice
may be a result of residual hypomorphic IRS1 function from the
more distal truncation at amino acid 211, or of the difference in
strain background (C3H/HeSnJ, except for a Swiss donor con-
genic fragment on chromosome 17).
The point mutation responsible for smla is likely to have arisen
as a random point mutation in the ES cell line that produced
SerpinB2 (15B11). A remote effect directly resulting from the
homologous recombination targeting procedure seems very un-
likely, given the physical distance between the SerpinB2 gene and
Irs1 (27 Mb). Extensive Southern blot analyses also detected no
evidence for an aberrant recombination as the result of the gene
targeting. Smla S57X homozygotes were observed among the
progeny of all six chimeric founders from injection of the 15B11
clone. However, an additional SerpinB2-targeted clone also de-
rived from the D3 ES cell line [SerpinB2 (10G3)] did not gen-
erate mice with the smla phenotype. Taken together, these
results suggest that the smla mutation either arose in the 15B11
clone shortly after targeting or that the S57X mutation is present
in a subclone within the D3 cell line.
Although ES cell lines are generally propagated for a limited
number of passages, new mutations would be expected to arise
randomly during each cell division in cell culture during the gene
targeting process. ES cells may also be hypersensitive to DNA
damage, readily undergoing apoptosis or differentiation to
remove the damaged cells from the totipotent pool (31, 32). As
ES cells have been demonstrated to have enhanced mutation
repair mechanisms for certain classes of mutations, such as
double strand break repair, the observed mutations surviving
propagation would be expected to be enriched for other classes,
such as point mutations, and further selected for those that have
either no deleterious or even positive growth effects on cultured
ES cells (31, 32).
Although not previously reported to our knowledge, sponta-
neous point mutations are likely to be a common event in gene
targeting experiments. Previous calculations based on human
disease mutation data estimated the rate of nonsense and other
clear loss-of-function mutations as approximately 3.4 × 10−6 per
locus per generation (33), in excellent agreement with recent
direct whole genome sequencing analysis of a family quartet
(34). Assuming that one human generation corresponds to ap-
proximately 35 cell divisions yields a loss-of-function mutation
rate of approximately 1 × 10−7 per locus per cell division. This
number is also consistent with directly measured mutation rates
at the Aprt and Hprt loci in murine ES cells (31, 35). The Ser-
pinB2 (15B11) allele was targeted in D3 ES cells (17) at ap-
proximately 30 cell culture passages from the isolation of the
original ES cell to establish the D3 line. An estimated additional
20 passages were required for cell line maintenance and the gene
targeting procedure. The assumption of approximately three cell
doublings per passage yields a total of approximately 150 cell
divisions, which predicts the accumulation of approximately
1.5 × 10−5 inactivating mutations per locus (or approximately 0.3
inactivating mutations per genome). This number may not fully
account for missense and regulatory mutations and is thus po-
tentially a significant underestimate. The majority of these
mutations would be unlinked to the targeted locus, and thus
likely to be lost during breeding to establish the line. However,
a linked mutation could confound analysis, particularly of early-
generation animals. Similar effects have been documented for
strain-specific passenger genes (6), resulting from transgenesis or
gene targeting in one mouse genetic background, subsequently
backcrossed into a second strain. Selection for the targeted or
transgenic allele results in retention of varying lengths of flanking
DNA from the original strain, generally in the range of 10 to 30
Mb and potentially containing hundreds of genetic variants, even
between highly inbred WT and transgenic littermates (6).
With the mutation frequencies estimated earlier, more than
0.6% of gene-targeted alleles would be expected to carry
Table 3. Evidence of strain modifier genes affecting the survival
of Irs1 S57X homozygous mice at 2 wk of age
Gene Irs1+/+ Irs1+/− Irs1−/− Total P value
C57BL/6J (N3–N4) 67 (29%) 160 (70%) 2 (0.1%) 229 <1.4 × 10−16
C57/129 F2 7 (15%) 27 (59%) 12 (26%) 46 0.29*
*Not significant.






a functionally significant spontaneous mutation within 30 Mb of
the targeted gene. Such a mutation would be coinherited with
the targeted allele, along with other strain-specific genetic dif-
ferences within the same interval, potentially leading to mis-
interpretation of the association of phenotype with the targeted
genotype, particularly if the conclusions are based on a single
clone (6, 36).
Although conflicting KO phenotypes resulting from strain-
specific modifier genes or differences in the anatomy of the
targeting constructs have been previously documented, the im-
pact of a new spontaneous mutation in a passenger gene should
be added to the list of potential confounding genomic effects
that must be taken into account for all gene targeting experi-
ments. Although this report documents a unique spontaneous
point mutation in a passenger gene, the “Fierce” phenotype
observed in Zfa-KO mice was previously shown to be caused by
a 44-kb ES cell deletion removing the Nr2e1 gene (located ap-
proximately 10 Mb from the Zfa gene) (37). These two reports
suggest that such spontaneous mutations may more frequently
complicate gene targeting experiments than previously sus-
pected. This is an important issue to consider in approaches to
saturate the mouse genome with a library of KO alleles, partic-
ularly if only a single clone per gene is produced and/or analyzed
(38). Taken together, these observations suggest that the analysis
of an unexpected gene targeted phenotype should be confirmed
by examination of mice derived from at least two independent
ES clones.
Materials and Methods
Generation of SerpinB2 Deficient smla and Normal Mouse Lines. The genera-
tion of SerpinB2-deficient mice was previously reported (17). A total of three
independent SerpinB2-deficient lines were generated, two [SerpinB2
(15B11) and SerpinB2 (13B5)] from the 129Sv D3 cell line and one [SerpinB2
(10G3)] from cell line CJ7 (39). Clone 15B11 from the D3 cell line was used to
generate six chimeric male founder mice, which were then mated to (C57BL/
6J × DBA/2J) F1 females. B6D2 F1 mice (stock no. 100006, http://jaxmice.jax.
org/strain/100006.html; Jackson Laboratory) were used for mating to the
original chimeras to increase numbers of offspring. The resulting pups,
which we designated F1, were then interbred to generate progeny, which
we designated as F2. DNA prepared from tail biopsies was genotyped at the
SerpinB2 locus as previously described (17). SerpinB2 (15B11) mice from each
of the six founder lines exhibited the distinctive smla phenotype and were
subjected to further genetic and phenotypic analysis. The SerpinB2 (13B5)
and SerpinB2 (10G3) lines were analyzed as previously reported (17). The
10G3 line (stock no. 007234, http://jaxmice.jax.org/strain/007234.html; Jack-
son Laboratory) has been deposited at Jackson Laboratory and has been
distributed to other investigators. All subsequent studies and reports from
other groups (14, 15, 40–42) were confined to the 10G3 line. All animal care
and experimental procedures complied with the Principles of Laboratory
and Animal Care established by the National Society for Medical Research
and were approved by the University of Michigan Committee on Use and
Care of Animals.
Initial Phenotypic Analysis of smla SerpinB2 (15B11) Deficient Mice. A total of
280 F2 progeny of the initial F1 intercross were used for weight analyses.
Pups were weighed at weaning. To reduce the effect on weight of litter size,
age at weaning, and maternal care, weights were normalized to the mean
weight of SerpinB2 WT mice within the same litter (n = 228; litters lacking
SerpinB2 WT mice were not included in this analysis). To analyze relative
growth, 11 mice from two litters were weighed every 2 to 3 d from birth
through 6 wk of age. Before tagging, mice were distinguished by colored
nontoxic marker. Kaplan–Meier analysis was performed based on survival
data from 100 mice. Sera collected from SerpinB2-deficient mice of the ini-
tial intercross were tested at Charles River Laboratories for the following
common infectious agents: SEN, PVM, MHV, MVM, GD-VII, REO-3, MPUL,
MPV, EDIM, LCMV, MAD, ECTRO, K, POLY, MTLV, MCMV, HANT, ECUN, and
CARB. The effect of maternal care was evaluated by fostering pups to WT
mothers (28). Autopsies were performed on one normal-sized and two smla
3-mo-old F2 mice.
DNA Analysis for Aberrant Targeting. DNA was prepared as previously de-
scribed (17) from ES cells of the three targeted SerpinB2-deficient lines as
well as control nontargeted ES cells. DNA was also prepared from mice
generated from the three SerpinB2-deficient clones. Probes included a 1-kb
ScaI/HindIII fragment of the SerpinB2 gene located 5′ to the targeting vector
(probe A) and an XbaI/EcoRI fragment located within the 3′ arm of the
targeting construct (probe B) as previously described (17). A SerpinB2 cDNA
probe was generated as a 1.7-kb PstI-ClaI fragment, and the neo probe
consisted of a 0.5-kb PCR-amplified fragment, generated with primers de-
scribed previously (17). Standard Southern blot analysis was performed on
DNA digested with BglI for analysis with probe A or ScaI for analysis with
probes B, SerpinB2 cDNA or neo. Further Southern blot analysis was per-
formed with probe B on mouse DNA digested with ApaI, NheI, or StuI.
Positional Cloning of smla. For genetic mapping, an intersubspecific outcross
was performed between an inbred strain of Mus musculus castaneus (CASA/
Rk) and three SerpinB2-deficient smla mice on a mixed Mus musculus
background (129S1/SvIMJ, C57BL/6J and DBA/2J). The (smla × CASA/Rk) F1
mice were intercrossed to produce 283 F2 generation progeny. At weaning,
pups were euthanized and weighed, and tail biopsy specimens were col-
lected. Weights of pups were normalized to the weight of WT pups in the
same litter, as described earlier. For the initial stage of mapping, smla mice
were defined as those with normalized weight ratios lower than 0.7. Mating
pairs were progeny tested to select those in which both parents carried the
smla allele. To exclude mice with runted phenocopies, only mating pairs
producing two or more smla pups that were nonrecombinant across the
candidate interval were used for subsequent mapping. Initially, 18 smlamice
were genotyped for 13 markers from mouse chromosome 1 (D1Mit124, 178,
332, 216, 8, 415, 10, 26, 218, 263, 498, 199, 266). Genotyping was performed
as previously described (43), and the 129S1/SvIMJ, C57BL/6J and DBA/2J M.
musculus alleles were considered as one equivalent class for mapping pur-
poses, as compared with the M. musculus castaneous allele.
For further analysis, 265 additional F2 mice from a (CASA/Rk × smla) F1
intercross were studied. After localization of smla between markers
D1Mit216 and D1Mit8, both small and normal-sized F2 progeny were gen-
otyped at these two markers. Mice recombinant between D1Mit216 and
D1Mit8 were genotyped at D1Mit44, 382, and 383 (three additional markers
located between D1Mit216 and D1Mit8).
Irs1 Sequence Analysis. A series of primer pairs were designed using the
primer3 program (http://biotools.umassmed.edu/bioapps/primer3_www.cgi)
to generate overlapping PCR amplicons approximately 500 bp in length that
span the entire coding region of Irs1 (44). PCR was performed on DNA iso-
lated from a mouse with the SerpinB2 (15B11) smla phenotype. PCR ampli-
cons were purified using the Qiaquick PCR gel extraction kit (Qiagen),
sequenced, and assembled into a contig using DNAStar (Lasergene), then
compared with the publicly available M. musculus sequence (GenBank ac-
cession no. NM_010570).
Genotyping the Irs1 Point Mutant. The Irs1 C170A point mutation was gen-
otyped by analysis of a 190-bp PCR product generated with the following
primers: 5′, CTT CTC AGA CGT GCG CAA GG; 3′, GTT GAT GTT GAA ACA GCT
CTC. The C170A mutation abolishes a Taq1 restriction site (TCGA to TAGA) at
position 143 of the PCR product.
Western Blotting. The quadriceps muscles of WT, heterozygous, and IRS1
Ser57X homozygous mutants were excised, snap-frozen, and homogenized.
Homogenates were then fractionated on a 4% to 12% SDS/PAGE gel and
probed with a rabbit anti-rat polyclonal antibody (45, 46). This antibody was
generated against a peptide corresponding to the sequence of the COOH-
terminal 14 aa of rat IRS1 (Millipore). The Western blot was run with the
SeeBlue Plus2 prestained standard (Invitrogen).
Influence of Disparate Genetic Contexts on Survival of Irs1-Deficient Mice.
Heterozygous Irs1 C170A point mutants were backcrossed to C57BL/6J for six
generations and segregated away from the SerpinB2-deficient allele. An in-
tercross of the N6 backcrossed heterozygous mice was analyzed for surviving
mice of each genotype atweaning. N6-backcrossedmicewere then outcrossed
to 129S1/SvIMJ and the F1 progeny intercrossed to produce the F2 generation.
Survival of each possible genotype of the F2 mice was assessed at 2 wk.
Statistics. Data from mouse crosses were statistically analyzed using the χ2
test. Weight differences were evaluated by t test. Survival was analyzed by
Kaplan–Meier method, with significance determined by the log-rank test.
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